The JAK2 V617F mutation is found in patients with blood-related diseases such as polycythemia vera, essential thrombocythemia and myelofibrosis. Ruxolitinib is effective as a JAK inhibitor, making it a prognostic factor in determining drug response. Detection of the JAK2 V617F mutation facilitates the classification of patients with MPD (myeloproliferative disease) into three levels of diagnostic certainty (possible, probable and definitive) and to determine which signal transduction therapy is appropriate for each patient. In addition, the WHO (World Health Organization) has recommended JAK2 V617F mutation testing as a clinical trial.
PNAClamp™ Mutation Detection Kit JAK2
For the detection of JAK2 mutations in tissue biopsies
Cat. No. PNAC-6001
Other products
Flocktype Mycoplasma Ms Ab (2 ELISA plates)
Cat. No. FT274602 For the detection of antibodies against Mycoplasma...
Biospin Total RNA Extraction Kit-100T-PCR/RT-PCR KIT(BSC63M1)
Effective kit to isolate total RNA from different sources. Simple,...
Ready-to-use 2% Agarose Gels (Eco-Green Staining)
Ref: TAE17 Precast gels can be your most convenient, fastest...
Biospin PCR Purification Kit 50T (BSC03S1)
The kit purifies DNA fragments in a simple, fast and...